Your browser doesn't support javascript.
loading
Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV.
Azizi, Hiva; Knapp, Jason P; Li, Yue; Berger, Alice; Lafrance, Marc-Alexandre; Pedersen, Jannie; de la Vega, Marc-Antoine; Racine, Trina; Kang, Chil-Yong; Mann, Jamie F S; Dikeakos, Jimmy D; Kobinger, Gary; Arts, Eric J.
Afiliación
  • Azizi H; Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
  • Knapp JP; Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1N 5A2, Canada.
  • Li Y; Department of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.
  • Berger A; Department of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.
  • Lafrance MA; Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
  • Pedersen J; Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
  • de la Vega MA; Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
  • Racine T; Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
  • Kang CY; Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Mann JFS; Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC G1V 0A6, Canada.
  • Dikeakos JD; Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
  • Kobinger G; Department of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.
  • Arts EJ; Bristol Veterinary School, University of Bristol, Langford House, Langford, BS40 5DU Bristol, UK.
Vaccines (Basel) ; 11(5)2023 May 12.
Article en En | MEDLINE | ID: mdl-37243081
Vesicular stomatitis virus (VSV) remains an attractive platform for a potential HIV-1 vaccine but hurdles remain, such as selection of a highly immunogenic HIV-1 Envelope (Env) with a maximal surface expression on recombinant rVSV particles. An HIV-1 Env chimera with the transmembrane domain (TM) and cytoplasmic tail (CT) of SIVMac239 results in high expression on the approved Ebola vaccine, rVSV-ZEBOV, also harboring the Ebola Virus (EBOV) glycoprotein (GP). Codon-optimized (CO) Env chimeras derived from a subtype A primary isolate (A74) are capable of entering a CD4+/CCR5+ cell line, inhibited by HIV-1 neutralizing antibodies PGT121, VRC01, and the drug, Maraviroc. The immunization of mice with the rVSV-ZEBOV carrying the CO A74 Env chimeras results in anti-Env antibody levels as well as neutralizing antibodies 200-fold higher than with the NL4-3 Env-based construct. The novel, functional, and immunogenic chimeras of CO A74 Env with the SIV_Env-TMCT within the rVSV-ZEBOV vaccine are now being tested in non-human primates.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza